China-based Suzhou Ribo Life Science Co., Ltd reportedly raised USD 40 million in a Series E1 financing round led by existing investors Panlin Capital and Trinity Innovation Fund. The small interfering RNA (siRNA) drug specialist had previously planned an IPO on Shanghai’s Sci-Tech Innovation Board (STAR) but withdrew it in May 2023.
Funding Details
Proceeds from the funding will support the global development and upgrade of small nucleic acid technology, with a focus on non-liver targeted delivery.
Product Pipeline
Ribo’s siRNA pipeline covers liver disease, cardiovascular disease, metabolic disease, ophthalmology, and more. The company completed a Phase Ia study for its hepatitis B virus (HBV) siRNA drug RBD1016 in healthy subjects, with its Phase Ib study in HBV carriers showing world-class safety and efficacy. Ribo aims to file for multiple Investigational New Drug (IND) applications this year.-Fineline Info & Tech
